Protective effects of amniotic fluid in the setting of necrotizing enterocolitis

Soham Dasgupta, Sunil Jain

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Necrotizing enterocolitis (NEC) is the most common life threatening condition affecting preterm infants. NEC occurs in 1-5% of all neonatal intensive care admissions and 5-10% of very low birth weight infants. The protective role of human breast milk (BM) has been well established. It has also been shown that amniotic fluid (AF) and BM have many similarities in terms of presence of growth and other immune-modulatory factors. This finding led to the initial hypothesis that AF may exert similar protective effects against the development of NEC, as does BM. Multiple studies have elucidated the presence of growth factors in AF and the protective effect of AF against NEC. Studies have also described possible mechanisms how AF protects against NEC. At present, research in this particular area is extremely active and robust. This review summarizes the various studies looking at the protective effects of AF against the development of NEC. It also provides an insight into future directions, the vast potential of AF as a readily available biologic medium, and the ethical barriers that must be overcome before using AF.

Original languageEnglish (US)
Pages (from-to)584-595
Number of pages12
JournalPediatric Research
Volume82
Issue number4
DOIs
StatePublished - Oct 1 2017

Fingerprint

Necrotizing Enterocolitis
Amniotic Fluid
Human Milk
Neonatal Intensive Care
Very Low Birth Weight Infant
Immunologic Factors
Premature Infants
Intercellular Signaling Peptides and Proteins
Growth

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Protective effects of amniotic fluid in the setting of necrotizing enterocolitis. / Dasgupta, Soham; Jain, Sunil.

In: Pediatric Research, Vol. 82, No. 4, 01.10.2017, p. 584-595.

Research output: Contribution to journalReview article

@article{5c4d32f86eef41a6a93005181c67b587,
title = "Protective effects of amniotic fluid in the setting of necrotizing enterocolitis",
abstract = "Necrotizing enterocolitis (NEC) is the most common life threatening condition affecting preterm infants. NEC occurs in 1-5{\%} of all neonatal intensive care admissions and 5-10{\%} of very low birth weight infants. The protective role of human breast milk (BM) has been well established. It has also been shown that amniotic fluid (AF) and BM have many similarities in terms of presence of growth and other immune-modulatory factors. This finding led to the initial hypothesis that AF may exert similar protective effects against the development of NEC, as does BM. Multiple studies have elucidated the presence of growth factors in AF and the protective effect of AF against NEC. Studies have also described possible mechanisms how AF protects against NEC. At present, research in this particular area is extremely active and robust. This review summarizes the various studies looking at the protective effects of AF against the development of NEC. It also provides an insight into future directions, the vast potential of AF as a readily available biologic medium, and the ethical barriers that must be overcome before using AF.",
author = "Soham Dasgupta and Sunil Jain",
year = "2017",
month = "10",
day = "1",
doi = "10.1038/pr.2017.144",
language = "English (US)",
volume = "82",
pages = "584--595",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Protective effects of amniotic fluid in the setting of necrotizing enterocolitis

AU - Dasgupta, Soham

AU - Jain, Sunil

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Necrotizing enterocolitis (NEC) is the most common life threatening condition affecting preterm infants. NEC occurs in 1-5% of all neonatal intensive care admissions and 5-10% of very low birth weight infants. The protective role of human breast milk (BM) has been well established. It has also been shown that amniotic fluid (AF) and BM have many similarities in terms of presence of growth and other immune-modulatory factors. This finding led to the initial hypothesis that AF may exert similar protective effects against the development of NEC, as does BM. Multiple studies have elucidated the presence of growth factors in AF and the protective effect of AF against NEC. Studies have also described possible mechanisms how AF protects against NEC. At present, research in this particular area is extremely active and robust. This review summarizes the various studies looking at the protective effects of AF against the development of NEC. It also provides an insight into future directions, the vast potential of AF as a readily available biologic medium, and the ethical barriers that must be overcome before using AF.

AB - Necrotizing enterocolitis (NEC) is the most common life threatening condition affecting preterm infants. NEC occurs in 1-5% of all neonatal intensive care admissions and 5-10% of very low birth weight infants. The protective role of human breast milk (BM) has been well established. It has also been shown that amniotic fluid (AF) and BM have many similarities in terms of presence of growth and other immune-modulatory factors. This finding led to the initial hypothesis that AF may exert similar protective effects against the development of NEC, as does BM. Multiple studies have elucidated the presence of growth factors in AF and the protective effect of AF against NEC. Studies have also described possible mechanisms how AF protects against NEC. At present, research in this particular area is extremely active and robust. This review summarizes the various studies looking at the protective effects of AF against the development of NEC. It also provides an insight into future directions, the vast potential of AF as a readily available biologic medium, and the ethical barriers that must be overcome before using AF.

UR - http://www.scopus.com/inward/record.url?scp=85029898016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029898016&partnerID=8YFLogxK

U2 - 10.1038/pr.2017.144

DO - 10.1038/pr.2017.144

M3 - Review article

VL - 82

SP - 584

EP - 595

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 4

ER -